Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price fell 4.4% on Monday . The company traded as low as $16.36 and last traded at $16.40, with a volume of 228,324 shares. The stock had previously closed at $17.16.

Several research firms have weighed in on HRTX. Jefferies Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a research note on Friday, June 24th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Finally, Noble Financial reaffirmed a “buy” rating and issued a $51.00 price target on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $51.50.

The firm has a 50-day moving average of $18.40 and a 200-day moving average of $19.43.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.92). On average, equities analysts expect that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current year.

In other Heron Therapeutics news, President Robert Rosen sold 200,000 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $23.23, for a total transaction of $4,646,000.00. Following the completion of the sale, the president now owns 178,968 shares of the company’s stock, valued at approximately $4,157,426.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Other large investors have recently made changes to their positions in the company. Swiss National Bank purchased a new stake in shares of Heron Therapeutics during the fourth quarter valued at $1,100,000. GAM Holding AG boosted its stake in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares in the last quarter. Russell Frank Co boosted its stake in Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares in the last quarter. California State Teachers Retirement System boosted its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares in the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.